Precision BioSciences (DTIL) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences (DTIL) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 48.0% versus a loss of 20.0%. Over five years, DTIL leads with a -97.2% price change compared with -97.8% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $282.5 million), about 1.1 times the size.
On valuation, X4 Pharmaceuticals trades at a lower trailing P/E (5.5x vs 29.6x for Precision BioSciences). Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -1218.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DTIL | XFOR |
|---|---|---|
| Share price | $7.40 | $3.00 |
| Market cap | $282.46M | $306.34M |
| 1-day change | +7.09% | +1.35% |
| YTD return | +77.88% | -25.00% |
| 1-year return | +48.00% | -20.00% |
| 5-year return | -97.23% | -97.79% |
| P/E ratio (TTM) | 29.60 | 5.45 |
| EPS (TTM) | $0.25 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $34.26M | $6.50M |
| Revenue growth (YoY) | -50.12% | +150.00% |
| Net income (latest FY) | $-45.72M | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | -152.19% | -1336.66% |
| Net margin | -133.45% | -1218.45% |
| 52-week high | $11.29 | $4.83 |
| 52-week low | $3.53 | $2.43 |
| Distance from 52-week high | -34.46% | -37.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +297.30% | +286.67% |
| Average volume | 319.79K | 877.70K |
| Shares outstanding | 38.17M | 102.11M |
| Employees | 69 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed XFOR by 68.0 percentage points over the past year.
- Precision BioSciences trades at a higher earnings multiple (29.6x vs 5.5x trailing P/E).
- Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -1218.4 cents for X4 Pharmaceuticals.
- X4 Pharmaceuticals grew revenue faster in its latest fiscal year (+150.00% vs -50.12%).
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
DTIL vs XFOR FAQ
Which is bigger, Precision BioSciences or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $282.46M for Precision BioSciences (DTIL).
Which stock has performed better over the past year, DTIL or XFOR?
DTIL returned +48.00% over the past 12 months, compared with -20.00% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DTIL or XFOR?
XFOR has the lower trailing P/E at 5.5, versus 29.6 for DTIL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Precision BioSciences and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.